Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06492304 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
A Phase 1 study of Acute Myeloid Leukemia and B-cell Lymphoma, sponsored by CRISPR Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 290
- Enrollment target
- 7
- Study locations
NCT06492304: Recruiting Phase 1 study of Acute Myeloid Leukemia and B-cell Lymphoma, sponsored by CRISPR Therapeutics.
NCT06492304 is a Phase 1 study of Acute Myeloid Leukemia and B-cell Lymphoma that is actively recruiting participants, run by CRISPR Therapeutics. The registered enrollment target is 290 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (152% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06492304, a Phase 1 study of Acute Myeloid Leukemia and B-cell Lymphoma, is actively recruiting participants, sponsored by CRISPR Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 290 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
Primary Outcome
For all cohorts: Incidence of Adverse events defined as dose-limiting toxicities
Conditions Studied
Interventions
- BIOLOGICAL CTX131
Study Locations (7)
New York
- Research Site 4 - New York
- Research Site 2 - The Bronx
Arizona
- Research Site 6 - Phoenix
California
- Research Site 5 - Stanford
Massachusetts
- Research Site 3 - Boston
Texas
- Research Site 1 - Houston
Victoria
- Research Site 7 - East Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2030-11 |
| Phase | Phase 1 |
What NCT06492304 shows while recruiting
NCT06492304 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (152% higher).
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which CTX131 is the first listed.
NCT06492304 lists 7 locations in 6 states (New York, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT06492304 about?
NCT06492304 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies". This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
What is the current status of trial NCT06492304?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2024-08-13. Estimated completion is 2030-11.
What conditions does trial NCT06492304 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, B-cell Lymphoma, T-Cell Lymphoma.
What interventions are being tested in trial NCT06492304?
The interventions under investigation include: CTX131 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06492304?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06492304 being conducted?
This trial has 7 study locations across Arizona, California, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06492304's enrollment target sits among peer trials
290 29th of 306 higher than 278 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI